ALDX — Stock Film
STOCK FILMSCENE 1/11ALDX · $1.58
Stock Expert AI presents
ALDX
Aldeyra Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Aldeyra Therapeutics, Inc. A quick introduction.

On the stock market since 2014, it operates in the world of health and science. It has 9 employees. Now — the numbers.

on the stock market since 2014
9 employees
$248.3M market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2021
$0
2022
$0
2023
$0
2024
$0
2025
In the vault right now:
$0
DEBT: $15.5M
At this pace, that money lasts about 2.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

What executives did with their own stock over the last 12 months:
39 buy2 sell

Executives buying with their own money is usually read as confidence in the company’s future.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
33
very weak

Clearly below the class average.

FINANCIAL STRENGTH
22
very weak

Clearly below the class average.

VALUATION
17
very weak

Clearly below the class average.

GROWTH
80
very strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
15
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 39 buys and 2 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $9.67514% above today’s price.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $33.8M against $0 in annual sales.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ALDX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ALDX is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (17/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film